Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of BCD-066 vs Aranesp in Healthy Volunteers
NCT03693950Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Mar 2017
- Primary completion
- Jul 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of darbepoetin alfa biosimilar (BCD-066) in anemia (2 arms), sponsored by BIOCAD. Primary endpoint: Area Under the Curve from time 0 to 72 hours. Started Mar 2017; status: completed.
02
Drugs
darbepoetin alfa biosimilar (BCD-066)
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03693950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693950.